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Abstract
Protein lysine methyltransferase G9a plays key roles in the transcriptional repression of a variety
of genes via dimethylation of lysine 9 on histone H3 (H3K9me2) of chromatin as well as
dimethylation of non-histone proteins including tumor suppressor p53. We previously reported the
discovery of UNC0321 (3), the most potent G9a inhibitor to date, via structure-based design and
structure activity relationship (SAR) exploration of the quinazoline scaffold represented by
BIX01294 (1). Despite its very high in vitro potency, compound 3 lacks sufficient cellular
potency. The design and synthesis of several generations of new analogs aimed at improving cell
membrane permeability while maintaining high in vitro potency resulted in the discovery of a
number of novel G9a inhibitors such as UNC0646 (6) and UNC0631 (7) with excellent potency in
a variety of cell lines and excellent separation of functional potency versus cell toxicity. The
design, synthesis and cellular SAR of these potent G9a inhibitors are described.
Introduction
The `writers' (the enzymes that produce post-translational modifications (PTMs)), the
`readers' (the proteins that recognize PTMs), and the `erasers' (the enzymes that remove
PTMs) of the histone code1, 2 are critical targets for manipulation to understand the role of
the histone code in human disease. Protein lysine methyltransferases (PKMTs), the methyl
`writers' of the histone code, catalyze the transfer of a methyl group from S-adenosyl-L-
methionine (SAM) to the ε-amino group of lysine residues of various proteins including
histones and non-histone proteins.3, 4 With the exception of DOT1L, all PKMTs contain the
evolutionarily conserved SET domain, named after Drosophila Su(var)3–9 (suppressor of
variegation 3–9), E(z) (enhancer of zeste), and trithorax5. Since the first PKMT was
characterized in 20006, more than 50 human PKMTs have been identified3, 4 and the
mechanistic, biochemical and biological functions of these proteins are still being
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elucidated. PKMTs display significant variations in protein substrate selectivity and the
degree of methylation on lysine from mono-, di-, to trimethylation. In the context of
epigenetic gene regulation, these different states of lysine methylation encode distinct
signals and are recognized by a host of protein modules such as Tudor and chromodomains,
MBT domains and PHD fingers, usually within larger proteins and chromatin remodeling
complexes that direct cellular processes such as chromatin packaging and transcriptional
regulation, and DNA repair, replication and metabolism.7, 8 PKMTs themselves are also
often components of large regulatory complexes and act in concert with other epigenetic
factors.9 Selective inhibition of individual PKMT catalytic activity in cellular systems
represents a valuable strategy to decipher the complex signaling mechanisms of histone and
protein lysine methylation. A `tool-kit' of potent, selective, and cell-penetrant chemical
probes10 of PKMTs will permit biological and therapeutic hypotheses to be tested with high
confidence in cell-based models of human biology and disease. However, very few such
small-molecule tools are available to the biomedical research community.11–13
G9a (also known as KMT1C or EHMT2) was initially identified as a H3K9
methyltransferase.14 It was later found that G9a could methylate various histone15 and non-
histone proteins including the tumor suppressor p53.16, 17 G9a is overexpressed in various
human cancers17–20 and knockdown of G9a inhibits cancer cell growth.18, 20–22 The di-
methylation of p53 K373 by G9a and GLP (also known as KMT1D or EHMT1), a closely
related methyltransferase that shares 80% sequence identity with G9a in their respective
SET domains and forms a heterodimer with G9a, results in the inactivation of p53, whose
loss of function is implicated in over 50% of cancers.17 In addition, G9a has been shown to
play a role in cocaine addiction,23 mental retardation,24 maintenance of HIV-1 latency25 and
DNA methylation in embryonic stem (ES) cells.26–28
The recent report by Jenuwein and colleagues of BIX01294 (1), the first selective small
molecule inhibitor of G9a and GLP,29, 30 was an important advance in the PKMT probe
discovery area (Figure 1). We have explored the 2,4-diamino-6,7-dimethoxyquinazoline
template represented by 1. Our initial structure-based design and synthesis in combination
with SAR exploration led to the discovery of potent and selective G9a inhibitors UNC0224
(2) and UNC0321 (3, the most potent G9a inhibitor (Morrison Ki = 63 pM) to date) and
valuable SAR for the quinazoline template.31, 32 Cheng and coworkers have also reported
SAR of the quinazoline scaffold that resulted in the discovery of E72 (4) as a potent and
selective GLP inhibitor.33 However, compounds 334 and 433 are less potent in cellular
assays than 1 even though 3 and 4 are more potent than 1 in in vitro biochemical assays.
Compound 1 is active at reducing the H3K9me2 levels in bulk histones and at G9a target
genes,29 but it has poor separation of functional potency versus cell toxicity.29, 34 We have
recently reported UNC0638 (5), a chemical probe of G9a/GLP with robust on-target
activities in cells and an excellent ratio of toxicity to functional potency (tox/function ratio,
which is determined dividing the EC50 value of the observed toxicity by the IC50 value of
the functional potency).34 Here we report the design and synthesis of novel analogs of
compound 3 aimed at improving cellular potency of this quinazoline series and the SAR of
these compounds in cell-based assays that led to the discovery of compound 5 and novel
G9a inhibitors such as UNC0646 (6) and UNC0631 (7), which have excellent tox/function
ratios in a variety of cell lines.
Results and Discussion
It was hypothesized that the poor cellular potency of compound 3 was likely due to its poor
cell membrane permeability and low lipophilicity (ALogP = 1.9). To improve cell
membrane permeability, and thus cellular potency of this chemical series, we exploited the
SAR at the 2-amino, 4-amino, and 7-aminoalkoxy regions of this quinazoline scaffold
Liu et al. Page 2













discovered previously. For the 7-aminoalkoxy region, the four groups (marked in blue in
Figure 2) that yield high in vitro potency32 were selected as affinity anchors. Because few
modifications to the 4-(piperidin-4-yl)amino moiety except the N-capping group (which
does not make interactions with the protein) on the piperidine nitrogen are tolerated,31, 32 the
three N-capping groups (marked in red in Figure 2) were selected to increase lipophilicity
while maintaining high in vitro potency. Since modifications to the 2-amino moiety are well
tolerated,31, 32 various homopiperazine, azepine, piperidine, and cyclohexyl groups (marked
in green in Figure 2) were selected to further increase lipophilicity. These combination
compounds were designed to achieve balanced in vitro potency and physicochemical
properties aiding cell penetration.
The inhibitory activity of these compounds on G9a was evaluated using the fluorescence-
based S-adenosyl-L-homocysteine hydrolase (SAHH)-coupled assay32 we previously
reported. The H3K9me2 antibody cell immunofluorescence In-Cell Western (ICW) assay34
recently developed by us was used to assess the cellular potency of these compounds. This
assay allows rapid processing of multiple compounds for H3K9me2 immunofluorescence
signal and normalization to cell number via the use of the nucleic acid dye DRAQ5. The
compounds were first evaluated in MDA-MB-231 cells because this cell line possesses
robust H3K9me2 levels. Most promising compounds were subsequently evaluated in a
number of other cancer and normal cell lines. Viability of cells after inhibitor treatment was
assessed by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay,
which measures the conversion of yellow MTT to purple formazan by cellular mitochondrial
reductase.
For the 7-aminoalkoxy region, compounds 2, 3, 8, and 9, the four most potent G9a inhibitors
(in biochemical assays) we previously reported,32 were evaluated in the ICW and MTT
assays (Table 1). Similar to compound 3, compound 2 showed poor potency in reducing
H3K9me2 levels in MDA-MB-231 cells even though it was highly potent in the G9a
enzyme inhibitory assay. On the other hand, compounds 8 and 9, which are more lipophilic
than compounds 2 and 3 as evident by their ALogP values, showed higher cellular potency
in the ICW assay. All four compounds had low cell toxicity (EC50 > 10 μM) in the MTT
assay. These initial findings validated our hypothesis that the poor cellular potency of
compound 3 was due to its low lipophilicity, and high cellular potency could be achieved by
increasing lipophilicity of this series. Based on these results, we selected the pyrrolidin-1-
ylpropoxy (8) and piperidin-1-ylpropoxy (9) groups as the preferred 7-aminoalkoxy moieties
for optimizing other regions of this quinazoline series.
To efficiently explore the 2-amino region, a new synthetic route (9 steps) was developed
(Scheme 1). Unlike our previously published synthetic route,32 this new synthesis allows us
to install various 2-amino groups at the last step of the synthetic sequence. Commercially
available methyl 4-hydroxy-3-methoxybenzoate (10) was reacted with 1-chloro-3-
iodopropane, followed by nitration, to afford the chloride 11. Substitution of the chloride
with pyrrolidine and subsequent reduction of the nitro group yielded the aniline 13.
Formation of urea from the aniline 13 and subsequent ring closure afforded the intermediate
15, which was then converted to the 2,4-dichloroquinazoline 16. Two consecutive chloro
displacement reactions by various amines provided the desired final products 17a – 17i in
good overall yields. Synthesis of compound 5, the 2-cyclohexyl analog of compounds 17a –
17i, from the intermediate 13 was reported by us previously.34
Compounds 17a – 17i and 5 were highly potent inhibitors (IC50 < 0.025 μM) in the G9a
SAHH-coupled biochemical assay (Table 2). Various N-capping groups (17a – 17g) on the
outer nitrogen of the homopiperazine moiety were well tolerated. In addition, azepine (17i),
piperidine (5), and cyclohexyl groups (5) also showed high in vitro potency. Importantly, in
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addition to maintaining high in vitro potency, these new compounds have improved
lipophilicity compared to compounds 2 and 3. We were pleased to find that the combination
of high in vitro potency and improved lipophilicity indeed resulted in high cellular potency
(IC50 < 0.5 μM in the ICW assay). In particular, more lipophilic compounds such as 17d
(ALogP 4.7), 17e (ALogP 5.0), 17g (ALogP 4.4), 17i (ALogP 4.2), and 5 (ALogP 4.8) had
cellular potency (IC50) equal to or less than 0.1 μM. Plotting cellular potency of the
inhibitors in Tables 1 and 2 and inhibitors to be discussed below as a function of ALogP
values of these inhibitors reveals that cellular potency strongly correlates with lipophilicity
(Figure 3). These results validated our design strategy for improving cellular potency.
Furthermore, cell toxicity of these highly potent G9a inhibitors was assessed using the MTT
assay. While most of these inhibitors had a relatively poor tox/function ratio (< 10),
compounds 17h, 17i, and 5 had a good separation of functional potency (reducing H3K9me2
levels) versus cell toxicity (tox/function ratio > 45). In particular, compound 5 had an
excellent tox/function ratio of 140.
Because compound 5 showed high cellular potency and excellent separation of functional
potency versus cell toxicity, we further investigated this 2-cyclohexyl quinazoline subseries.
Thus, a new 9-step synthesis (Scheme 2) was developed to efficiently explore the 7-
aminoalkoxy region. Benzyl protection of commercially available 4-hydroxy-3-
methoxybenzonitrile (18), followed by nitration and subsequent reduction afforded the
aniline 19. Amide formation from the aniline 19 and subsequent cyclization yielded the
quinazolinone 20, which was then converted to the 4-chloro quinazoline 21. Displacement
of the chloro intermediate 21 with 1-isopropylpiperidin-4-amine, followed by debenzylation
afforded the phenol 23. Mitsunobu reactions of the phenol 23 with various amino alcohols
yielded the desired compounds 24a, 24b, and 5.
Compared to compound 5, compound 24a was less potent in the ICW assay (Table 3). This
is likely due to the about 10-fold lower potency of compound 24a in the G9a biochemical
assay although 24a is slightly more lipophilic. The combination of lower in vitro potency
and lower lipophilicity of compound 24b compared to compound 5 resulted in lower cellular
potency as expected (Figure 3). Interesting, both compounds 24a and 24b had low cell
toxicity, similar to compound 5.
We next synthesized a number of combination compounds including 6, 7, and 25 – 27 using
the synthetic route outlined in Scheme 1 and evaluated them in the G9a SAHH-coupled,
ICW, and MTT assays. Compounds 6, 7, 25, and 26, which had high in vitro potency versus
G9a and improved lipophilicity, were highly potent (IC50 < 0.06 μM) in reducing H3K9me2
levels in MDA-MB-231 cells and had low cell toxicity (Table 4). In particular, compounds 6
and 7 were more potent than compound 5 and had a similar tox/function ratio in MDA-
MB-231 cells (Table 5). On the other hand, many combination compounds failed to improve
cellular potency and reduce cell toxicity. For example, compound 27 was about 10-fold less
potent in reducing cellular levels of H3K9me2 than compounds 6 and 7. The lower cellular
potency of compound 27 is likely due to the combination of its lower G9a in vitro potency
and lower lipophilicity compared to compounds 6 and 7 (Figure 3).
Because compounds 6 and 7 showed excellent separation of functional potency versus cell
toxicity in MDA-MB-231 cells, these two compounds were further evaluated in a variety of
cell lines to characterize their cellular potency and cell toxicity. As shown in Table 5,
compounds 6 and 7 were highly potent in reducing H3K9me2 levels in these cell lines and
had low cell toxicity. Similar to compound 5, compounds 6 and 7 had excellent tox/function
ratios in these cell lines. In particular, compound 6 had an outstanding tox/function ratio in
MCF7 (470), 22RV1 (510), and IMR90 (360) cells, making this compound potentially more
useful for investigating G9a biology in these specific cell lines. In general, compounds 6 and
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7 had higher cellular potency, but also higher cell toxicity compared to compound 5. While
compound 5 has been selected as a chemical probe of G9a/GLP34 because of its low cell
toxicity and lower molecular weight, compounds 6 and 7 are valuable alternative tool
compounds that may be more suitable for investigating specific cellular systems (vide
supra).
The excellent selectivity of compound 5 for G9a/GLP over a wide range of epigenetic and
nonepigenetic targets has been reported previously.34 Consistent with these results, we
found that compound 6 was also a potent GLP inhibitor (IC50 < 0.015 μM in the GLP
SAHH-coupled assay) and highly selective for G9a/GLP over several other PKMTs and
PRMTs including SETD7 (a H3K4 PKMT), SUV39H2 (a H3K9 PKMT), SETD8 (a H4K20
PKMT) and PRMT3 (IC50 > 10 μM in the SAHH-coupled assays against these 4 targets).
In addition to methylating histone substrates,14, 15, 35 G9a and GLP dimethylate K373 of the
tumor suppressor p53.17 We reported the robust effects of compound 5 on reducing
H3K9me2 levels in various cellular systems.34 However, the effects of the quinazoline
series on cellular levels of p53 K373me2 have not been reported previously. Thus, we
evaluated the effects of compound 5 on reducing p53 K373me2 levels in H1299 cells (p53
negative), which were co-transfected with p53 and G9a or GLP. As shown in Figure 4,
compound 5 at 0.25 μM effectively inhibited the dimethylation of p53 K373 without
significant changes to levels of total p53 and G9a or GLP in H1299 cells. These results
together with our previous H3K9me2 findings34 strongly suggest that compound 5 is an
effective inhibitor that blocks the methyltransferase activity of G9a and GLP in cells.
Conclusions
To improve cellular potency of the quinazoline series, we designed several generations of
novel analogs aimed at achieving balanced G9a in vitro potency and physicochemical
properties aiding cell penetration. New synthetic routes to efficiently synthesize these novel
compounds were developed. SAR studies of these newly synthesized compounds in the G9a
biochemical (SAHH-coupled), cell-based functional (anti-H3K9me2 ICW), and cell toxicity
(MTT) assays validated our inhibitor design strategy and resulted in the discovery of
compounds 6 and 7, which had high cellular potency and excellent separation of functional
potency versus cell toxicity in a variety of cell lines. Compounds 6 and 7 together with
compound 5, the previously reported G9a chemical probe, are valuable small molecule tools
for the biomedical research community to further investigate the biology of G9a and its role
in chromatin remodeling as well as PTMs of other proteins.
Experimental Section
Chemistry General Procedures
HPLC spectra for all compounds were acquired using an Agilent 6110 Series system with
UV detector set to 254 nm. Samples were injected (5 μL) onto an Agilent Eclipse Plus 4.6 ×
50 mm, 1.8 μM, C18 column at room temperature. A linear gradient from 10% to 100% B
(MeOH + 0.1% acetic acid) in 5.0 min was followed by pumping 100% B for another 2
minutes with A being H2O + 0.1% acetic acid. The flow rate was 1.0 mL/min. Mass spectra
(MS) data were acquired in positive ion mode using an Agilent 6110 single quadrupole mass
spectrometer with an electrospray ionization (ESI) source. High-resolution mass spectra
(HRMS) were acquired using a Shimadzu LCMS-IT-TOF time-of-flight mass spectrometer.
Nuclear Magnetic Resonance (NMR) spectra were recorded at Varian Mercury spectrometer
with 400 MHz for proton (1H NMR) and 100 MHz for carbon (13C NMR); chemical shifts
are reported in ppm (δ).36 Preparative HPLC was performed on Agilent Prep 1200 series
with UV detector set to 220 nm. Samples were injected onto a Phenomenex Luna 75 × 30
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mm, 5μM, C18 column at room temperature. The flow rate was 30 mL/min. A linear
gradient was used with 10% of MeOH (A) in 0.1 % TFA in H2O (B) to 100% of MeOH (A).
All compounds that were evaluated in biological assays had > 95% purity using the HPLC
methods described above.
2,4-Dichloro-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (16)
A solution of compound 13 (3.6 g, 11.67 mmol) (prepared from commercially available
methyl 3-methoxy-4-hydroxy benzoate (10) according to the procedures described
previously34) in acetic acid (20 mL) and water (10 mL) was treated with sodium cyanate
(1.14 g, 17.5 mmol) while stirring, and then the mixture was stirred overnight at rt. After the
resulting mixture was concentrated, the desired crude product 14 was obtained as a brown
slurry oil. MS (ESI): 352 [M + H]+. A mixture of crude compound 14 in MeOH (30 mL)
was neutralized with 10% NaOH aqueous solution, and then an additional 10% NaOH
aqueous solution (10 mL) was added. The mixture was refluxed for 3h, cooled to room
temperature, and neutralized with concentrated HCl to give a precipitate. The resulting
precipitate was collected and dried to provide the desired crude product 15 (2.60 g). MS
(ESI): 320 [M + H]+. A mixture of the crude compound 15 (2.60 g, 8.14 mmol) and N,N–
diethylaniline (1.3 mL, 8.14 mmol) in POCl3 (45 mL) was heated at reflux for 7h. The
reaction mixture was concentrated in vacuo and saturated aq NaHCO3 (50 mL) was added.
The resulting mixture was extracted with chloroform (30 mL × 3). The combined organic
layers were dried, concentrated and purified by flash column chromatography on silica gel
(0 – 20% MeOH / CH2Cl2) to afford the title compound 16 as a yellow solid (2.06 g, 50%
over three steps). 1H NMR (400 MHz, CDCl3) δ 7.30 (s, 1H), 7.25 (s, 1H), 4.26 (t, J = 6.5
Hz, 2H), 4.02 (s, 3H), 2.74 (t, J = 7.3 Hz, 2H), 2.64 (m, 4H), 2.23–2.15 (m, 2H), 1.87–1.79
(m, 4H). MS (ESI): 356 [M + H]+.
N-(1-isopropylpiperidin-4-yl)-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-amine (17a)
A mixture of compound 16 (0.72 g, 2.02 mmol), 1-isopropylpiperidin-4-amine (0.87 g, 6.06
mmol) (this amine and other non-commercially available amines were prepared according to
the literature procedures37), and DIEA (0.67 mL, 4.04 mmol) in THF (10 mL) was stirred
overnight at rt. After concentration in vacuo, the crude product was purified by silica gel
chromatography (0 –20% MeOH (1% NH3) / CH2Cl2) to afford the desired product 2-
chloro-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-amine as a yellow solid (0.88 g, 94% yield). 1H NMR (400 MHz,
CDCl3) δ 7.12 (s, 1H), 6.78 (s, 1H), 5.36 (d, J = 7.7 Hz, 1H), 4.31–4.20 (m, 1H), 4.17 (t, J =
6.7 Hz, 2H), 3.96 (s, 3H), 2.90 (d, J = 11.9 Hz, 2H), 2.84–2.73 (m, 1H), 2.67–2.59 (m, 2H),
2.57–2.46 (m, 4H), 2.45–2.34 (m, 2H), 2.22–2.05 (m, 4H), 1.84–1.71 (m, 4H), 1.65– 1.55
(m, 2H), 1.07 (d, J = 6.6 Hz, 6H). MS (ESI): 462 [M + H]+. Then, a mixture of the
intermediate (71 mg, 0.149 mmol), 1-methylhomopiperazine (34 mg, 0.30 mmol), and TFA
(68 mg, 0.60 mmol) in i-PrOH (0.25 mL) was heated by microwave irradiation to 160 °C for
15 min in a sealed tube. After concentration in vacuo, the crude product was purified by
preparative HPLC with a gradient from 10% of MeOH (A) in 0.1% TFA in H2O (B) to
100% of MeOH (A). The resulting product was basified with saturated aq NaHCO3 and
extracted with CH2Cl2 to afford the title compound 17a as a white solid (64 mg, 79%
yield). 1H NMR (400 MHz, CDCl3) δ 6.87 (s, 1H), 6.71 (s, 1H), 4.98 (d, J = 7.1 Hz, 1H),
4.13 (t, J = 6.8 Hz, 2H), 4.08–3.98 (m, 1H), 3.97–3.92 (m, 2H), 3.89–3.82 (m, 5H), 2.91–
2.84 (m, 2H), 2.78–2.69 (m, 1H), 2.69–2.63 (m, 2H), 2.61–2.56 (m, 2H), 2.55–2.50 (m, 2H),
2.51–2.44 (m, 4H), 2.34 (s, 3H), 2.29 (td, J = 11.5, 2.2 Hz, 2H), 2.19–2.11 (m, 2H), 2.11–
2.02 (m, 2H), 2.01–1.94 (m, 2H), 1.79–1.70 (m, 4H), 1.54 (ddd, J = 14.9, 11.8, 3.7 Hz, 2H),
1.04 (d, J = 6.6 Hz, 6H). 13C NMR (100 MHz, CDCl3, two overlapping peaks) δ 158.70,
158.10, 154.05, 149.76, 145.22, 107.08, 102.79, 101.67, 67.40, 59.07, 57.46, 56.76, 54.58,
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54.25, 53.01, 48.77, 47.88, 46.83, 45.98, 32.75, 28.64, 27.98, 23.56, 18.60. HPLC: 97%; tR
1.18 min. MS (ESI): 540 [M + H]+.
2-(4-Ethyl-1,4-diazepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-amine (17b)
Compound 17b was prepared as a white solid by the same procedures as the preparation of
compound 17a (80% yield). 1H NMR (400 MHz, CDCl3) δ 6.89 (s, 1H), 6.71 (s, 1H), 4.95
(d, J = 7.1 Hz, 1H), 4.15 (t, J = 6.8 Hz, 2H), 4.10–4.01 (m, 1H), 3.98–3.92 (m, 2H), 3.90–
3.82 (m, 5H), 2.94–2.85(m, 2H), 2.80–2.71 (m, 3H), 2.64–2.46 (m, 10H), 2.36–2.26 (m,
2H), 2.20–2.13 (m, 2H), 2.12–2.04 (m, 2H), 2.02–1.93 (m, 2H), 1.82–1.70 (m, 4H), 1.56
(ddd, J = 14.6, 12.0, 3.5 Hz, 2H), 1.13–0.99 (m, 9H). 13C NMR (100 MHz, CDCl3) δ
158.75, 158.15, 154.10, 149.80, 145.26, 107.12, 102.81, 101.69, 67.43, 56.84, 55.94, 54.64,
54.47, 54.30, 53.08, 51.71, 48.76, 47.92, 46.28, 45.88, 32.77, 28.68, 27.97, 23.60, 18.63,
12.51. HPLC: 97%; tR 1.14 min. MS (ESI): 554 [M + H]+.
2-(4-Isopropyl-1,4-diazepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-amine (17c)
Compound 17c was prepared as an off-white solid by the same procedures as the preparation
of compound 17a (82% yield). 1H NMR (400 MHz, CDCl3) δ 6.87 (s, 1H), 6.72 (s, 1H),
4.98 (d, J = 7.1 Hz, 1H), 4.13 (t, J = 6.8 Hz, 2H), 4.09–3.99 (m, 1H), 3.93–3.87 (m, 2H),
3.88–3.80 (m, 5H), 2.95–2.83 (m, 3H), 2.78–2.69 (m, 3H), 2.62–2.53 (m, 4H), 2.53–2.43
(m, 4H), 2.33–2.23 (m, 2H), 2.20–2.11 (m, 2H), 2.10–2.02 (m, 2H), 1.94–1.85 (m, 2H),
1.81–1.68 (m, 4H), 1.54 (ddd, J = 14.6, 12.0, 3.6 Hz, 2H), 1.04 (d, J = 6.6 Hz, 6H), 0.98 (d,
J = 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3, two overlapping peaks) δ 158.74, 158.14,
154.00, 149.85, 145.12, 107.08, 102.78, 101.72, 67.39, 56.77, 55.20, 54.57, 54.25, 53.02,
52.26, 50.68, 48.76, 47.89, 47.80, 45.77, 32.76, 28.78, 28.65, 23.56, 18.61. HPLC: 99%; tR
1.25 min. MS (ESI): 568 [M + H].
2-(4-Cyclohexyl-1,4-diazepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-
(pyrrolidin-1-yl)propoxy)quinazolin-4-amine (17d)
Compound 17d was prepared as a white solid by the same procedures as the preparation of
compound 17a (78% yield). 1H NMR (400 MHz, CDCl3) δ 6.87 (s, 1H), 6.72 (s, 1H), 4.98
(d, J = 7.1 Hz, 1H), 4.13 (t, J = 6.8 Hz, 2H), 4.09–3.97 (m, 1H), 3.92–3.78 (m, 7H), 2.91–
2.84 (m, 2H), 2.83–2.77 (m, 2H), 2.77–2.68 (m, 1H), 2.65–2.60 (m, 2H), 2.58 (t, J = 7.4 Hz,
2H), 2.53–2.39 (m, 5H), 2.33–2.24 (m, 2H), 2.18–2.10 (m, 2H), 2.10–2.00 (m, 2H), 1.92–
1.83 (m, 2H), 1.82–1.68 (m, 8H), 1.62–1.47 (m, 3H), 1.25–1.06 (m, 5H), 1.04 (d, J = 6.5 Hz,
6H).13C NMR (100 MHz, CDCl3) δ 158.73, 158.13, 153.98, 149.86, 145.09, 107.07,
102.76, 101.72, 67.37, 64.43, 56.75, 54.56, 54.24, 53.01, 52.64, 51.26, 48.75, 47.99, 47.89,
45.78, 32.75, 29.34, 28.85, 28.64, 26.49, 26.19, 23.55, 18.60. HPLC: 99%; tR 2.16 min. MS
(ESI): 608 [M + H]+.
2-(4-(Cyclohexylmethyl)-1,4-diazepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-
(pyrrolidin-1-yl)propoxy)quinazolin-4-amine (17e)
Compound 17e was prepared as a white solid by the same procedures as the preparation of
compound 17a (81% yield). 1H NMR (400 MHz, CDCl3) δ 6.87 (s, 1H), 6.73 (s, 1H), 4.99
(d, J = 7.1 Hz, 1H), 4.13 (t, J = 6.8 Hz, 2H), 4.09–3.98 (m, 1H), 3.94–3.87 (m, 2H), 3.87–
3.76 (m, 5H), 2.91–2.83 (m, 2H), 2.78–2.67 (m, 3H), 2.62–2.52 (m, 4H), 2.52–2.43 (m, 4H),
2.29 (t, J = 10.7 Hz, 2H), 2.22 (d, J = 6.9 Hz, 2H), 2.15 (d, J = 10.8 Hz, 2H), 2.11–2.01 (m,
2H), 1.96–1.86 (m, 2H), 1.81–1.48 (m, 11H), 1.47–1.34 (m, 1H), 1.26–1.10 (m, 3H), 1.04
(d, J = 6.5 Hz, 6H), 0.88–0.74 (m, 2H). 13C NMR (100 MHz, CDCl3, two overlapping
peaks) δ 158.75, 158.10, 153.99, 149.86, 145.10, 107.07, 102.76, 101.72, 67.38, 64.33,
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56.75, 55.34, 54.56, 54.24, 53.01, 48.77, 47.89, 46.62, 45.96, 36.32, 32.74, 32.00, 28.64,
27.93, 26.96, 26.30, 23.56, 18.60. HPLC: 99%; tR 2.39 min. MS (ESI): 622 [M + H]+.
N-(1-isopropylpiperidin-4-yl)-6-methoxy-2-(4-phenyl-1,4-diazepan-1-yl)-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-amine (17f)
Compound 17f was prepared as a yellow solid by the same procedures as the preparation of
compound 17a (74% yield). 1H NMR (400 MHz, CDCl3) δ 7.22 (t, J = 7.9 Hz, 2H), 6.90 (s,
1H), 6.80–6.72 (m, 3H), 6.65 (t, J = 7.2 Hz, 1H), 4.99 (d, J = 7.1 Hz, 1H), 4.18 (t, J = 6.8
Hz, 2H), 4.14–3.99 (m, 3H), 3.90 (s, 3H), 3.71–3.61 (m, 4H), 3.51 (t, J = 6.2 Hz, 2H), 2.96–
2.87 (m, 2H), 2.83–2.70 (m, 1H), 2.62 (t, J = 7.3 Hz, 2H), 2.58– 2.45 (m, 4H), 2.32 (t, J =
10.7 Hz, 2H), 2.22–2.05 (m, 6H), 1.85–1.72 (m, 4H), 1.58 (ddd, J = 14.7, 11.9, 3.5 Hz, 2H),
1.08 (d, J = 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 158.40, 158.31, 154.12, 149.87,
147.69, 145.37, 129.52, 115.76, 111.66, 107.14, 102.93, 101.63, 67.42, 56.81, 54.60, 54.29,
53.06, 50.56, 48.83, 47.93, 47.78, 47.10, 46.12, 32.86, 28.67, 24.89, 23.59, 18.61. HPLC:
98%; tR 3.29 min. MS (ESI): 602 [M + H]+.
2-(4-Benzyl-1,4-diazepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-amine (17g)
Compound 17g was prepared as an off-white solid by the same procedures as the
preparation of compound 17a (78% yield). 1H NMR (400 MHz, CDCl3) δ 7.25–7.12 (m,
5H), 6.82 (s, 1H), 6.67 (s, 1H), 4.95 (d, J = 7.0 Hz, 1H), 4.08 (t, J = 6.8 Hz, 2H), 4.02–3.91
(m, 1H), 3.90–3.84 (m, 2H), 3.84–3.75 (m, 5H), 3.55 (s, 2H), 2.87–2.77 (m, 2H), 2.74–2.61
(m, 3H), 2.59–2.50 (m, 4H), 2.47–2.38 (m, 4H), 2.21 (t, J = 11.3 Hz, 2H), 2.15–1.95 (m,
4H), 1.94–1.83 (m, 2H), 1.73–1.63 (m, 4H), 1.48 (ddd, J = 14.6, 11.9, 3.5 Hz, 2H), 0.98 (d,
J = 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 158.71, 158.12, 154.04, 149.76, 145.19,
139.61, 128.91, 128.20, 126.87, 107.06, 102.79, 101.72, 67.39, 62.30, 56.76, 56.28, 54.98,
54.58, 54.25, 53.02, 48.76, 47.87, 46.58, 46.01, 32.72, 28.63, 28.15, 23.56, 18.58. HPLC:
98%; tR 2.27 min. MS (ESI): 616 [M + H]+.
N-(1-isopropylpiperidin-4-yl)-6-methoxy-2-(piperidin-1-yl)-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-amine (17h)
Compound 17h was prepared as a white solid by the same procedures as the preparation of
compound 17a (76% yield). 1H NMR (400 MHz, CDCl3) δ 6.90 (s, 1H), 6.75 (s, 1H), 5.10
(d, J = 7.2 Hz, 1H), 4.21–4.01 (m, 3H), 3.87 (s, 3H), 3.80–3.73 (m, 4H), 2.98–2.86 (m, 2H),
2.82–2.72 (m, 1H), 2.65–2.57 (m, 2H), 2.58–2.45 (m, 4H), 2.40–2.28 (m, 2H), 2.20–2.12
(m, 2H), 2.12–2.02 (m, 2H), 1.82–1.69 (m, 4H), 1.69–1.53 (m, 8H), 1.07 (d, J = 6.6 Hz,
6H). 13C NMR (100 MHz, CDCl3) δ 158.95, 158.27, 154.01, 149.36, 145.46, 106.97,
102.93, 101.65, 67.35, 56.71, 54.74, 54.24, 53.02, 48.48, 47.89, 45.18, 32.47, 28.54, 26.07,
25.19, 23.56, 18.51. HPLC: 97%; tR 2.92 min. MS (ESI): 511 [M + H]+.
2-(Azepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-amine (17i)
Compound 17i was prepared as a white solid by the same procedures as the preparation of
compound 17a (78% yield). 1H NMR (400 MHz, CDCl3)δ6.89 (s, 1H), 6.72 (s, 1H), 4.96 (d,
J = 6.9 Hz, 1H), 4.15 (t, J = 6.8 Hz, 2H), 4.11–4.00 (m, 1H), 3.87 (s, 3H), 3.77 (t, J = 5.9
Hz, 4H), 2.93–2.85 (m, 2H), 2.80–2.68 (m, 1H), 2.60 (t, J = 7.4 Hz, 2H), 2.55–2.44 (m, 4H),
2.35–2.24 (m, 2H), 2.17 (d, J = 11.3 Hz, 2H), 2.13–2.02 (m, 2H), 1.85–1.67 (m, 8H), 1.63–
1.47 (m, 6H), 1.05 (d, J = 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3)δ158.76, 158.15,
154.03, 149.91, 145.04, 107.06, 102.71, 101.81, 67.41, 56.84, 54.61, 54.29, 53.06, 48.83,
47.94, 46.99, 32.82, 28.69, 28.66, 27.53, 23.59, 18.62. HPLC: 98%; tR 3.09 min. MS (ESI):
525 [M + H]+.
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Cyclohexanecarbonyl chloride (1.25 mL, 9.2 mmol) was added into a solution of compound
19 (1.95 g, 7.64 mmol) (prepared from commercially available 4-hydroxy-3-
methoxybenzonitrile (18) according to the procedures described previously31, 32) and DIEA
(1.90 mL, 11.5 mmol) in cosolvent DMF : DCM (10 mL : 5 mL) at 0 °C. The reaction
mixture was stirred overnight at rt, 25 mL of water was added, and the resulting mixture was
extracted with CH2Cl2 (15 mL × 3). The combined organic solvent was dried with sodium
sulfate, concentrated, and used in the next step without further purification. A mixture of the
product, 30 wt% H2O2 (20 mL) and NaOH (400 mg, 10.0 mmol) in ethanol (100 mL) was
stirred for 2 hours under reflux. After adding 100 mL of water, the reaction mixture was
cooled to rt and the resulting precipitate was collected, washed with water and dried to
afford the title compound 20 as a white solid (1.35 g, 48% yield over 2 steps). 1H NMR (400
MHz, CDCl3)δ9.63 (s, 1H), 7.60 (s, 1H), 7.50–7.30 (m, 5H), 7.15 (s, 1H), 5.26 (s, 2H), 3.99
(s, 3H), 2.66–2.53 (m, 1H), 2.03 (d, J = 12.2 Hz, 2H), 1.96–1.86 (m, 2H), 1.83–1.74 (m,
1H), 1.68–1.52 (m, 2H), 1.49–1.24 (m, 3H).
7-(Benzyloxy)-4-chloro-2-cyclohexyl-6-methoxyquinazoline (21)
A mixture of the compound 20 (1.32 g, 3.61 mmol) and N,N–diethylaniline (0.30 mL, 1.80
mmol) in POCl3 (20 mL) was heated at reflux for 4h. The reaction mixture was concentrated
in vacuo and saturated aq NaHCO3 (20 mL) was added. The resulting mixture was extracted
with chloroform (20 mL × 3). The combined organic layers were dried, concentrated and
purified by flash column chromatography on silica gel (0 – 10% ethyl acetate / hexanes) to
afford the title compound 21 as a yellow solid (1.10 g, 79% yield). 1H NMR (400 MHz,
CDCl3)δ7.51–7.30 (m, 7H), 5.30 (s, 2H), 4.04 (s, 3H), 2.92 (tt, J = 11.7, 3.4 Hz, 1H), 2.10–
1.99 (m, 2H), 1.93–1.84 (m, 2H), 1.79–1.64 (m, 3H), 1.49–1.27 (m, 3H).
7-(Benzyloxy)-2-cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxyquinazolin-4-amine (22)
A mixture of compound 21 (0.68 g, 1.77 mmol), 1-isopropylpiperidin-4-amine (0.77 g, 5.41
mmol), and DIEA (0.60 mL, 3.60 mmol) in i-PrOH (3.0 mL) was heated by microwave
irradiation to 160 °C for 15 min in a sealed tube. After concentration in vacuo, the crude
product was purified by silica gel chromatography (0 –10% MeOH / CH2Cl2) to afford the
title compound 22 as a white solid (0.81 g, 94% yield). 1H NMR (400 MHz, MeOH-
d4)δ7.52 (s, 1H), 7.45 (d, J = 7.2 Hz, 2H), 7.34 (t, J = 7.3 Hz, 2H), 7.31–7.24 (m, 1H), 7.11
(s, 1H), 5.18 (s, 2H), 4.27–4.19 (m, 1H), 3.94 (s, 3H), 2.98 (d, J = 11.7 Hz, 2H), 2.81–2.71
(m, 1H), 2.69–2.57 (m, 1H), 2.35 (t, J = 11.4 Hz, 2H), 2.13 (d, J = 11.4 Hz, 2H), 1.91–1.82




A mixture of compound 22 (0.81 g, 1.65 mmol), 1,4-cyclohexadiene (1.6 mL, 16.5 mmol)
and 10 wt % Pd/C (250 mg) in ethanol (16 mL) was heated to reflux 2h. The reaction
mixture was filtered and concentrated to provide the debenzylated product 23 as a yellow
solid which was used without purification. MS (ESI): 399 [M + H]+. Under nitrogen gas,
DIAD (270 μL, 1.38 mmol) was added into an ice-cooled mixture of compound 21 (110 mg,
0.276 mmol), 3-(pyrrolidin-1-yl)propan-1-ol (142 mg, 1.10 mmol) and PPh3 (399 mg, 1.52
mmol) in THF (4.0 mL). The reaction mixture was stirred overnight at rt. After
concentration in vacuo, the crude product was purified by preparative HPLC with a gradient
from 10% of MeOH (A) in 0.1% TFA in H2O (B) to 100 % of MeOH (A). The resulting
product was basified with a saturated solution of NaHCO3 and extracted with CH2Cl2 to
afford 56 mg of the desired product 5 as a white solid (91 mg, 65% yield over 2 steps). The
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Compound 24a was prepared as a white solid from compound 23 and 3-(piperidin-1-
yl)propan-1-ol via Mitsunobu reaction (52% over two steps). 1H NMR (400 MHz,
CDCl3)δ7.13 (s, 1H), 6.82 (s, 1H), 5.22 (d, J = 7.3 Hz, 1H), 4.25–4.07 (m, 3H), 3.88 (s, 3H),
2.93–2.84(m, 2H), 2.81–2.63 (m, 2H), 2.48–2.25 (m, 8H), 2.19 (d, J = 11.3 Hz, 2H), 2.08–
1.90 (m, 4H), 1.81 (d, J = 12.6 Hz, 2H), 1.75–1.47 (m, 9H), 1.47–1.17 (m, 5H), 1.05 (d, J =
6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3)δ169.44, 157.93, 153.68, 148.40, 147.38, 108.51,
106.73, 100.07, 67.73, 56.43, 55.78, 54.64, 54.62, 48.59, 47.97, 47.85, 32.67, 32.01, 26.49,
26.48, 26.32, 26.08, 24.53, 18.56. HPLC: 99%; tR 3.10 min. MS (ESI): 524 [M + H]+.
2-Cyclohexyl-7-(2-(2-(dimethylamino)ethoxy)ethoxy)-N-(1-isopropylpiperidin-4-yl)-6-
methoxyquinazolin-4-amine (24b)
Compound 24b was prepared as a white solid from compound 23 and 2-(2-
(dimethylamino)ethoxy)ethanol via Mitsunobu reaction (36% over two steps). 1H NMR
(400 MHz, CDCl3)δ7.11 (s, 1H), 6.83 (s, 1H), 5.22 (d, J = 7.2 Hz, 1H), 4.27–4.13 (m, 3H),
3.92–3.83 (m, 5H), 3.61 (t, J = 5.8 Hz, 2H), 2.93–2.85 (m, 2H), 2.80–2.64 (m, 2H), 2.48 (t, J
= 5.8 Hz, 2H), 2.40–2.31 (m, 2H), 2.22 (s, 6H), 2.19 (d, J = 10.5 Hz, 2H), 1.95 (d, J = 11.9
Hz, 2H), 1.86–1.76 (m, 2H), 1.75–1.50 (m, 5H), 1.46–1.21 (m, 3H), 1.05 (d, J = 6.5 Hz,
6H). 13C NMR (100 MHz, CDCl3)δ169.49, 157.94, 153.43, 148.39, 147.26, 108.52, 107.00,
100.20, 69.62, 69.01, 68.19, 58.84, 56.39, 54.61, 48.62, 47.98, 47.86, 45.91, 32.67, 32.01,
26.49, 26.32, 18.58. HPLC: 99%; tR 2.98 min. MS (ESI): 514 [M + H]+.
N-(1-cyclohexylpiperidin-4-yl)-2-(4-isopropyl-1,4-diazepan-1-yl)-6-methoxy-7-(3-
(piperidin-1-yl)propoxy)quinazolin-4-amine (6)
Compound 6 was prepared as a white solid by the same procedures as the preparation of
compound 17a (81% yield). 1H NMR (400 MHz, CDCl3)δ6.87 (s, 1H), 6.72 (s, 1H), 4.99 (d,
J = 7.1 Hz, 1H), 4.11 (t, J = 6.8 Hz, 2H), 4.08–3.98 (m, 1H), 3.93–3.88 (m, 2H), 3.87–3.78
(m, 5H), 3.17–3.00 (m, 1H), 2.96–2.85 (m, 3H), 2.78–2.70 (m, 2H), 2.60–2.52 (m, 2H),
2.49–2.23 (m, 8H), 2.14 (d, J = 11.1 Hz, 2H), 2.07–1.98 (m, 2H), 1.94–1.71 (m, 6H), 1.66–
1.47 (m, 7H), 1.45–1.35 (m, 2H), 1.22 (p, J = 11.7 Hz, 4H), 1.15–1.03 (m, 1H), 0.98 (d, J =
6.6 Hz, 6H). 13C NMR (100 MHz, CDCl3)δ158.75, 158.12, 154.00, 149.85, 145.12, 107.05,
102.78, 101.72, 67.50, 63.86, 56.75, 55.86, 55.20, 54.66, 52.27, 50.69, 48.82, 48.27, 47.78,
45.77, 32.90, 29.05, 28.79, 26.59, 26.47, 26.14, 26.10, 24.56, 18.61. HPLC: 100%; tR 2.25




Compound 7 was prepared as a white solid by the same procedures as the preparation of
compound 17a (81% yield). 1H NMR (400 MHz, CDCl3)δ6.88 (s, 1H), 6.72 (s, 1H), 4.97 (d,
J = 6.9 Hz, 1H), 4.13 (t, J = 6.8 Hz, 2H), 4.10–4.00 (m, 1H), 3.94–3.88 (m, 2H), 3.88–3.79
(m, 5H), 2.97–2.88 (m, 1H), 2.88–2.81 (m, 2H), 2.80–2.71 (m, 2H), 2.62–2.54 (m, 2H),
2.50–2.42 (m, 2H), 2.41–2.32 (m, 4H), 2.19–1.98 (m, 8H), 1.96–1.85 (m, 2H), 1.82–1.36
(m, 14H), 1.30–1.09 (m, 3H), 0.99 (d, J = 6.6 Hz, 6H), 0.93–0.80 (m, 2H). 13C NMR (100
MHz, CDCl3)δ158.79, 158.16, 154.05, 149.87, 145.17, 107.11, 102.81, 101.69, 67.55,
65.89, 56.78, 55.90, 55.23, 54.70, 53.30, 52.28, 50.73, 48.59, 47.80, 45.79, 35.57, 32.45,
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32.10, 28.82, 26.95, 26.64, 26.31, 26.15, 24.61, 18.65. HPLC: 99%; tR 2.56 min. MS (ESI):
636 [M + H]+. HRMS (ESI) calcd for C37H62N7O2 [M + H]+: 636.4965. Found: 636.4962.
2-(4-Isopropyl-1,4-diazepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(piperidin-1-
yl)propoxy)quinazolin-4-amine (25)
Compound 25 was prepared as a white solid by the same procedures as the preparation of
compound 17a (78% yield). 1H NMR (400 MHz, CDCl3)δ6.87 (s, 1H), 6.72 (s, 1H), 4.98 (d,
J = 7.1 Hz, 1H), 4.12 (t, J = 6.8 Hz, 2H), 4.09–3.99 (m, 1H), 3.95–3.88 (m, 2H), 3.88–3.78
(m, 5H), 2.97–2.83 (m, 3H), 2.78–2.68 (m, 3H), 2.60–2.53 (m, 2H), 2.49–2.40 (m, 2H),
2.40–2.24 (m, 6H), 2.15 (d, J = 11.1 Hz, 2H), 2.08–1.98 (m, 2H), 1.96–1.84 (m, 2H), 1.61–
1.48 (m, 6H), 1.45–1.36 (m, 2H), 1.05 (d, J = 6.5 Hz, 6H), 0.98 (d, J = 6.5 Hz, 6H). 13C
NMR (100 MHz, CDCl3, two overlapping peaks)δ158.76, 158.14, 154.03, 149.86, 145.14,
107.07, 102.77, 101.74, 67.51, 56.77, 55.87, 55.21, 54.67, 54.58, 52.28, 50.70, 48.76, 47.90,
47.80, 45.78, 32.77, 28.80, 26.60, 26.11, 24.57, 18.61. HPLC: 98%; tR 1.40 min. MS (ESI):
582 [M + H]+.
N-(1-cyclohexylpiperidin-4-yl)-6-methoxy-2-(4-methyl-1,4-diazepan-1-yl)-7-(3-(piperidin-1-
yl)propoxy)quinazolin-4-amine (26)
Compound 26 was prepared as a white solid by the same procedures as the preparation of
compound 17a (83% yield). 1H NMR (400 MHz, CDCl3)δ6.87 (s, 1H), 6.72 (s, 1H), 5.03 (d,
J = 7.1 Hz, 1H), 4.11 (t, J = 6.8 Hz, 2H), 4.07–3.98 (m, 1H), 3.97–3.90 (m, 2H), 3.88–3.79
(m, 5H), 3.27–3.08 (m, 1H), 2.96–2.86 (m, 2H), 2.70–2.62 (m, 2H), 2.58–2.50 (m, 2H),
2.48–2.24 (m, 11H), 2.13 (d, J = 11.0 Hz, 2H), 2.06–1.93 (m, 4H), 1.90–1.71 (m, 4H), 1.66–
1.48 (m, 7H), 1.46–1.33 (m, 2H), 1.22 (p, J = 12.0 Hz, 4H), 1.13–1.00 (m, 1H). HPLC:
99%; tR 2.26 min. MS (ESI): 594 [M + H]+.
2-(Azepan-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(piperidin-1-
yl)propoxy)quinazolin-4-amine (27)
Compound 27 was prepared as a white solid by the same procedures as the preparation of
compound 17a (75% yield). 1H NMR (400 MHz, CDCl3)δ6.88 (s, 1H), 6.72 (s, 1H), 4.95 (d,
J = 7.0 Hz, 1H), 4.13 (t, J = 6.8 Hz, 2H), 4.10–4.00 (m, 1H), 3.87 (s, 3H), 3.78 (t, J = 6.0
Hz, 4H), 2.93–2.85 (m, 2H), 2.80–2.68 (m, 1H), 2.50–2.42 (m, 2H), 2.41–2.24 (m, 6H), 2.17
(d, J = 10.8 Hz, 2H), 2.0–1.98 (m, 2H), 1.83–1.73 (m, 4H), 1.62–1.49 (m, 10H), 1.45–1.36
(m, 2H), 1.05 (d, J = 6.5 Hz, 6H). 13C NMR (100 MHz, CDCl3)δ158.81, 158.15, 154.03,
149.98, 145.03, 107.06, 102.70, 101.80, 67.52, 56.82, 55.90, 54.68, 54.60, 48.82, 47.94,
46.97, 32.83, 28.67, 27.54, 26.63, 26.13, 24.59, 18.62. HPLC: 100%; tR 3.06 min. MS
(ESI): 539 [M + H]+.
ALogP calculation
ALogP values were calculated using Pipeline Pilot v7.5 (Accelrys Software Inc., San Diego,
2009).
Experimental procedures for SAHH-coupled assays
The previously described enzyme-coupled assay38 was optimized and employed to assay the
activity of histone methyltransferases. This assay utilizes SAHH to hydrolyze the
methyltransfer product SAH to homocysteine and adenosine in the presence of adenosine
deaminase which converts adenosine to inosine. The homocysteine concentration is then
determined through conjugation of its free sulfhydryl moiety to a thiol-sensitive fluorophore,
ThioGlo (Calbiochem). For IC50 determinations, assay mixtures were prepared in 25 mM
potassium phosphate buffer pH 7.5, 1 mM EDTA, 2 mM MgCl2, 0.01% Triton X-100 with 5
μM SAHH, 0.3 U/mL of adenosine deaminase from Sigma, 25 μM SAM, and 15 μM
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ThioGlo. G9a, GLP, SETD7, SETD8, PRMT3 and SUV39H2 were assayed at 25 nM, 100
nM, 200 nM, 250 nM, 500 nM and 100 nM, respectively. Inhibitors were added at
concentrations ranging from 4 nM to 16 μM. After 2 min incubation, reactions were initiated
by addition of the histone peptides: 10 μM H3(1–25) for G9a, 20 μM H3(1–25) for GLP,
100 μM H3(1–25) for SETD7, 500 μM H4(1–24) for SETD8, 10 μM H4(1–24) for PRMT3
and 200 μM H3K9Me1 (1–15) for SUV39H2. The methylation reaction was followed by
monitoring the increase in fluorescence using Biotek Synergy2 plate reader with 360/40 nm
excitation filter and 528/20 nm emission filter for 20 min in 384 well-plate format. Activity
values were corrected by subtracting background caused by the peptide or the protein. IC50
values were calculated using Sigmaplot. Standard deviations were calculated from two
independent experiments.
Experimental procedures for ICW and MTT assays
MDA-MB-231, PC3, HCT116 cells were cultured in RPMI with 10% FBS, 22RV1 cells in
alphaMEM and 10% FBS, MCF7 and IMR90 cells in DMEM with 10% FBS. Cells were
treated with inhibitors for 48 h.
In-Cell Western (ICW) assay
Cells were seeded at 5–10 thousand cells in black walled 96 well plates (Greiner) and
exposed to various inhibitor concentrations for 48h. The media was removed and 2%
Formaldehyde in PBS for fixation was added for 15 min. After five washes with 0.1% Triton
X100 in PBS, cells were blocked for 1h with 1% BSA in PBS. Three out of four replicates
were exposed to the primary H3K9me2 antibody, Abcam #1220 at 1/800 dilution in 1%
BSA, PBS for 2 h. One replicate was reserved for the background control. The wells were
washed five times with 0.1% Tween 20 in PBS, then secondary IR800 conjugated antibody
(LiCor) and nucleic acid-intercalating dye, DRAQ5 (LiCor) added for 1 h. After 5 washes
with 0.1% Tween 20 PBS, the plates were read on an Odyssey (LiCor) scanner at 800 nm
(H3K9me2 signal) and 700 nm (DRAQ5 signal). Fluorescence intensity was quantified,
normalized to the background, then to the DRAQ5 signal, and expressed as a percentage of
control. IC50s were calculated using GraphPad Prizm statistical package with sigmoidal
variable slope dose response curve fit.
MTT assay
The media was removed and replaced with DMEM 10% FBS without phenol red
supplemented with 1mg/ml of MTT and incubated for 1–2 h. Live cells reduce yellow MTT
to purple formazan. The resulting formazan was solubilized in acidified isopropanol and 1%
Triton. Formazan signal absorbance was measured at 570 nm and corrected for the 650 nm
background. The data was analysed as above.
Experimental procedures for the p53 K373me2 assay
H1299 cells were transfected with 1 μg p53 expressing vector and 11 μg G9a or GLP
expressing vector. Immediately after transfection, cells were treated with 0.25 μM of
compound 5 and incubate for 24 h. Cells were then lysed in NET buffer (50 mM Tris-HCl,
pH 8.0, 0.1% NP40, 5 mM EDTA, 150 mM NaCl with protease inhibitors) and followed by
immunoprecipitation with DO1 antibody, which recognizing the total p53. Protein A agarose
beads were added to collect the immunoprecipitated complex. The immunoprecipitated
complex was subject to the Western blot analysis using p53 K373me2 antibody. For p53 and
G9a/GLP detection, whole cell lysate was used.
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Abbreviations
H3K9me2 dimethylation of lysine 9 on histone H3
SAR structure activity relationships
PTMs post-translational modifications
PKMTs protein lysine methyltransferases
SAM S-adenosyl-L-methionine
SET suppressor of variegation 3–9, enhancer of zeste, and trithorax
MBT domains malignant brain tumor domains
PHD plant homeo domain
KMT1C lysine methyltransferase 1C
EHMT2 euchromatic histone lysine methyltransferase 2
H3K9 histone H3 lysine 9
p53 K373 lysine 373 of p53
KMT1D lysine methyltransferase 1D
EHMT1 euchromatic histone lysine methyltransferase 1
ES cells embryonic stem cells
tox/function ratio ratio of toxicity to functional potency
SAHH S-adenosyl-L-homocysteine hydrolase
ICW in-cell western
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
PRMT protein arginine methyltransferase
p53 K373me2 dimethylation of p53 lysine 373
SAH S-adenosyl-L-homocysteine.
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Structures of known G9a/GLP inhibitors.29, 31–34
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Compounds designed to achieve balanced in vitro potency and physicochemical properties
aiding cell penetration to improve cellular potency.
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Analysis of cellular potency of G9a inhibitors as a function of their ALogP values reveals
that cellular potency increases as lipophilicity increases for inhibitors that have similar in
vitro potency. The inhibitors are color-coded with their G9a in vitro potency.
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Compound 5 at 0.25 M effectively inhibited the dimethylation of p53 K373 in H1299 cells.
p53 expression vector was co-transfected with or without expression vectors for G9a or GLP
into H1299 cells. Immediately after transfection, cells were treated with compound 5 or
DMSO for 24 h. Cellular levels of p53 K373me2, total p53 and G9a or GLP were subject to
western blot analysis using antibodies.
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Synthesis of compounds 17a
a(a) 1-Chloro-3-iodopropane, K2CO3, CH3CN, reflux; (b) HNO3, Ac2O, 0 °C to rt, 75%
over two steps; (c) pyrrolidine, K2CO3, NaI, cat. tetrabutylammonium iodide, CH3CN,
reflux, 81%; (d) Fe dust, NH4OAc, AcOEt-H2O, reflux, 63%; (e) NaOCN, AcOH, H2O, rt;
(f) NaOH, H2O, MeOH, reflux; (g) N,N-diethylaniline POCl3, reflux, 50% over three steps;
(h) 1-isopropylpiperidin-4-amine, DIEA, THF, rt, 94%; (i) various amines, CF3COOH, i-
PrOH, 160 °C, Microwave, 74% to 82%.
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Synthesis of compounds 24 and 5a
a(a) BnBr, K2CO3, DMF, rt; (b) HNO3, Ac2O, 0 °C to rt; (c) Fe dust, NH4Cl, i-PrOH-H2O,
reflux, 67% over 3 steps; d) cyclohexane carbonyl chloride, DIEA, DMF-DCM, 0 °C to rt;
(e) NaOH, H2O2, EtOH, reflux, 48% over 2 steps; (f) N,N-diethylaniline, POCl3, reflux,
79%; (g) 1-isopropylpiperidin-4-amine, DIEA, i-PrOH, 160°C, Microwave, 94%; (h) Pd/C,
1,4-cyclohexadiene, EtOH, reflux; (j) various amino alcohols, PPh3, DIAD, THF, 0 °C to rt,
36% to 65% over 2 steps.
Liu et al. Page 22




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Med Chem. Author manuscript; available in PMC 2012 September 8.
